Key Points
- Disc Medicine COO Jonathan Yen-Wen Yu sold 8,796 shares at an average price of $83.12, generating $731,123.52. His remaining stake fell 13.94% to 54,324 shares, and the sale follows several additional disposals since June.
- Disc Medicine shares opened at $82.67, above their 50-day and 200-day moving averages of $76.56 and $69.95, respectively. The stock has traded between $40.00 and $99.50 over the past year and has a market capitalization of about $316.6 million.
- Analyst sentiment remains broadly positive, with 10 Buy ratings, one Hold, and one Sell; the average price target is $106.50. The company also reported quarterly EPS of -$1.54, beating the consensus estimate of -$1.71.
Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) COO Jonathan Yen-Wen Yu sold 300 shares of the firm's stock in a transaction on Monday, August 24th. The stock was sold at an average price of $82.53, for a total transaction of $24,759.00. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares of the company's stock, valued at approximately $4,483,359.72. This represents a 0.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Jonathan Yen-Wen Yu also recently made the following trade(s):
- On Tuesday, August 25th, Jonathan Yen-Wen Yu sold 8,796 shares of Disc Medicine stock. The shares were sold at an average price of $83.12, for a total transaction of $731,123.52.
- On Wednesday, August 12th, Jonathan Yen-Wen Yu sold 804 shares of Disc Medicine stock. The shares were sold at an average price of $82.64, for a total value of $66,442.56.
- On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The stock was sold at an average price of $82.50, for a total value of $8,250.00.
- On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The shares were sold at an average price of $72.50, for a total value of $21,750.00.
- On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The stock was sold at an average price of $72.66, for a total transaction of $704,802.00.
- On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total transaction of $1,287,764.28.
Disc Medicine Stock Up 0.3%
NASDAQ:IRON opened at $82.67 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. The company's fifty day moving average price is $76.56 and its 200-day moving average price is $69.95. Disc Medicine, Inc. has a 1-year low of $40.00 and a 1-year high of $99.50. The firm has a market capitalization of $316.63 million, a P/E ratio of -12.56 and a beta of 1.00.
Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($1.71) by $0.17. As a group, equities research analysts anticipate that Disc Medicine, Inc. will post -6.61 EPS for the current year.
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Disc Medicine in a research report on Friday, July 17th. Wall Street Zen raised shares of Disc Medicine from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. HC Wainwright lifted their price objective on shares of Disc Medicine from $118.00 to $120.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Morgan Stanley reissued an "overweight" rating and set a $90.00 target price on shares of Disc Medicine in a research note on Monday, August 17th. Finally, Wedbush restated an "outperform" rating and issued a $88.00 price target on shares of Disc Medicine in a research note on Wednesday, June 10th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $106.50.
Read Our Latest Analysis on IRON
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the company. State of Wyoming acquired a new stake in Disc Medicine during the 2nd quarter worth $25,000. ANTIPODES PARTNERS Ltd acquired a new position in Disc Medicine during the fourth quarter worth about $33,000. Allworth Financial LP acquired a new position in Disc Medicine during the second quarter worth about $46,000. Nykredit A S purchased a new stake in Disc Medicine during the 2nd quarter valued at about $103,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Disc Medicine in the 4th quarter valued at about $141,000. 83.70% of the stock is owned by institutional investors and hedge funds.
About Disc Medicine
(
Get Free Report)
Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.
The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
